Anatoly Dritschilo, MD, was appointed to professor and chairman, Department of Radiation Medicine, at Georgetown University School of Medicine, and chief of service, MedStar Georgetown University Hospital, in 2010. Previously, Dr. Dritschilo served as interim chair of the Department of Oncology and as interim director of the Lombardi Comprehensive Cancer Center, Georgetown University Medical Center.
In the course of his clinical career, Dr. Dritschilo has treated more than 5,000 patients with cancers of the breast, prostate, lung, gastrointestinal tract, brain tumors and pediatric cancers. He has been instrumental in bringing state-of-the-art therapies and technologies to the hospital, including Proton Therapy with HYPERSCAN™ , CyberKnife SRS and SBRT services. MedStar Georgetown was one of the first CyberKnife sites on the East Coast, leading to its current position as a national leader in volume, experience and expertise. MedStar Georgetown is the first hospital in the Washington, DC metropolitan area to offer proton therapy and the first in the world to offer proton therapy with HYPERSCAN™.
Dr. Dritschilo is a prolific researcher, with a cumulative total of more than $20 million in NIH awards and nearly 250 peer-reviewed, published articles. He is a regular reviewer and editor for prominent scientific and medical publications, a sought-after presenter at national and international meetings and a frequent guest lecturer at medical schools around the county. The holder of a dozen US patents and diplomat of the American College of Radiology, Dr. Dritschilo received his medical degree from the College of Medicine of New Jersey followed by a residency in radiation therapy and a fellowship in radiation oncology at Harvard Medical School. After a brief stint at Tufts University-New England Medical Center, Dr. Dritschilo joined Georgetown in 1979.
Philosophy of Care
Each patient presents with a unique set of cancer-related and personal circumstances that are best evaluated and treated by a multidisciplinary team for optimal outcomes.
Bhatia S, Baig NA, Timofeeva O, Pasquale EB, Hirsch K, MacDonald TJ, Dritschilo A, Lee YC, Henkemeyer M, Rood B, Jung M, Wang XJ, Kool M, Rodriguez O, Albanese C, Karam SD. Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization. Oncotarget. 2015 Mar 30. [Epub ahead of print] PubMed PMID: 25879388.
Gurka MK, Chen LN, Bhagat A, Moures R, Kim JS, Yung T, Lei S, Collins BT, Krishnan P, Suy S, Dritschilo A, Lynch JH, Collins SP. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol. 2015 Feb 19;10(1):44. doi: 10.1186/s13014-015-0351-6. PubMed PMID: 25890265; PubMed Central PMCID: PMC4358866.
Janowski EM, Kole TP, Chen LN, Kim JS, Yung TM, Collins BT, Suy S, Lynch JH, Dritschilo A, Collins SP. Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer. Front Oncol. 2015 Jul 3;5:151. doi: 10.3389/fonc.2015.00151. eCollection 2015. PubMed PMID: 26191507; PubMed Central PMCID: PMC4490223.
Paydar I, Kim BS, Cyr RA, Rashid H, Anjum A, Yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP. Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging. Front Oncol. 2015 Sep 1;5:194. doi: 10.3389/fonc.2015.00194. eCollection 2015. PubMed PMID: 26389077; PubMed Central PMCID: PMC4556038.
Kole TP, Tong M, Wu B, Lei S, Obayomi-Davies O, Chen LN, Suy S, Dritschilo A, Yorke E, Collins SP. Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. Acta Oncol. 2016 Jan;55(1):52-8. doi: 10.3109/0284186X.2015.1037011. Epub 2015 May 14. PubMed PMID: 25972264.